Characterization of Biochemical and Functional Effects of Antiplatelet Drugs as a Key to Their Clinical Development

• References

• 1 Bom GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
• 2 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294
• 3 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B₂production in healthy subjects. Thromb Res 1980; 17: 317-327
• 4 Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. I Clin Invest 1986; 77: 590-594
• 5 Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B₂to urinary 11-dehydro-thromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70
• 6 Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B₂metabolites in humans. Thromb Res 1987; 47: 647-656
• 7 Reilly IA G, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186
• 8 Born GV R, Hume M. Effects of numbers and sizes of platelet aggregates on optical density of plasma. Nature 1967; 215: 1027-1029
• 9 Latimer P, Born GV R, Michail F. Application of high-scattering theory to the optical effects associated with the morphology of blood platelets. Arch Biochem Biophys 1977; 180: 151-159
• 10 Thompson NT, Scrutton MC, Wallis RB. Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986; 41: 615-626
• 11 Nichols AR, Bosmann HB. Platelet aggregation: newly quantified using non-empirical parameters. Thromb Haemostas 1979; 42: 679-693
• 12 Benner KU, Tamblyn CH, Swank RL, Seaman GV F. Platelet count ratio (PCR) as an additional parameter in the quantitation of platelet aggregation in vitro. Thromb Res 1980; 17: 801-808
• 13 Frojmovic MM, Milton JG, Gear AR L. Platelet aggregation measured in vitro by microscopic and electronic particle counting. Methods Enzymol 1989; 169: 134-149
• 14 Hause LL, Retzinger GS, Megan PA. Rapid determination of the rate constant of agonist-induced association of single platelets. Thromb Res 1991; 61: 105-112
• 15 Gear AR L. Rapid reactions of platelets studied by a quenched-flow approach: aggregation kinetics. J Lab Clin Med 1982; 100: 866-886
• 16 Frojmovic MM, Milton JG, Duchastel A. Microscopic measure-ments of platelet aggregation reveal a low ADP-dependent process distinct from turbidimetrically measured aggregation. J Lab Clin Med 1983; 101: 964-976
• 17 Leung LL K. Role of thrombospondin in platelet aggregation. J Clin Invest 1984; 74: 1764-1772
• 18 Pedvis LG, Wong T, Frojmovic MM. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by stable prostacyclin analogue (Iloprost). Thromb Haemostas 1988; 59: 323-328
• 19 Rocca B, De Cristofaro R, Della Ventura M, Bizzi B, Landolfi R. Kinetics of free platelet decrease after ADP: effect of fibrinogen binding inhibitors. Platelets. 1995 in press
• 20 FitzGerald GA, Reilly IA G, Pedersen AK. he biochemical pharmacology of thromboxane synthetase inhibition in man. Circulation 1985; 72: 1194-1201
• 21 Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J. harac-terization of N,N'-bis(3-picolyl)-4-methoxy-isophthalamide (pico- tamide) as a dual thromboxane synthase inhibitor/thromboxane A₂ receptor antagonist in human platelets. Thromb Haemostas 1989; 61: 479-484
• 22 Neri Serneri GG, Gensini GF, Poggesi L, Modesti PA, Rostagno C, Boddi M, Gori AM, Martini F, leri A, Margheri M, Abbate R. he role of extraplatelet thromboxane A₂in unstable angina investigated with a dual thromboxane A₂inhibitor: importance of activated monocytes. Coronary Artery Dis 1994; 5: 137-145
• 23 Minuz P, Lechi C, Arosio E, Guzzo P, Zannoni M, Lauciello C, Lechi A. ffect of picotamide on platelet aggregation and on throm-boxane A₂production in vivo. Thromb Haemostas 1991; 65: 312-316
• 24 Balsano F, Violi F. DEP group: Effect of picotamide on the clinical progression of peripheral vascular disease. Circulation 1993; 87: 1563-1569
• 25 Patrignani P, Filabozzi P, Patrono C. elective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372
• 26 Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Catella F, Davi G, Forni L. linical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-1183
• 27 FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Brash AR. ndogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688
• 28 De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell'Amico F, L'Abbate A, Patrignani P, Patrono C. qual antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemostas 1985; 54: 528-532
• 29 Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet treatment.. Part I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
• 30 The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.. Lancet 1990; 336: 827-830
• 31 Juul-Moller S, Edvardsson N, Jahnmatz B. or the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-1425
• 32 The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebro-vascular ischaemic events.. Lancet 1991; 338: 1345-1349
• 33 Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. hromboxane biosynthesis and platelet function in type-II diabetes mellitus. N Engl J Med 1990; 322: 1769-1776
• 34 Davi G, Notarbartolo A, Catalano I, Averna M, Barbagallo C, Ciabattoni G, Patrono C. ncreased thromboxane biosynthesis in type Ha hypercholesterolemia. Circulation 1992; 85: 1792-1797
• 35 Koudstaal PJ, Ciabattoni G, Van Gijn I, Nieuwenhuis HK, De Groot P, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 1993; 24: 219-222
• 36 Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GV R, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas 1990; 63: 163-168
• 37 Smith WL. rostanoid biosynthesis and mechanisms of action. Am I Physiol 1992; 263 F 181-191 F
• 38 Cipollone F, Patrignani P, Greco A, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. ifferential suppression of enhanced thromboxane biosynthesis in unstable angina by indobufen and aspirin. Eur Heart J. 1995 in press abstract
• 39 Patrignani P, Panara MR, Greco A, Fusco O, Natoii C, lacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J, Patrono C. iochemical and pharmacological characterization of the cyclooxy-genase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705-1712
• 40 Davi G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. nhibition of thromboxane bio-synthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb 1993; 13: 1346-1349
• 41 ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus.. Early treatment diabetic retinopathy study report 14. JAMA 1992; 268: 1292-1300
• 42 Landolfi R, Rocca B, Patrono C. leeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Hematol. 1995 in press
• 43 Landolfi R, Ciabattoni G, Patrignani P, Castellana MA L, Pogliani E, Bizzi B, Patrono C. ncreased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971
• 44 Landolfi R. ong-term safety of low-dose aspirin in polycythemia vera. J Investig Med. 1995 in press abstract
• 45 Van Kooten F, Ciabattoni G, Patrono C, Schmitz PI M, van Gijn J, Koudstaal PJ. vidence for episodic platelet activation in acute ischemic stroke. Stroke. 1994; 25: 278-281